Table 1. Sampling fraction and additional resistance among RR-TB patients in the study.
| Country | n1,2 (%) stored | n3 (%) included | n (%) new cases | n (%) pre-XDR4 | n (%) XDR4 |
|---|---|---|---|---|---|
| Benin | 15 (52) | 14 (93) | 0 (0) | NA5 | NA |
| Burkina Faso | 29 (85) | 5 (17) | 0 (0) | 0 (0) | 0 (0) |
| Burundi | 34 (56) | 32 (94) | 0 (0) | 0 (0) | 0 (0) |
| Cameroon | 145 (82) | 133 (92) | 9 (6.7) | 2 (1.5) | 0 (0) |
| CAR | 37 (82) | 35 (95) | 0 (0) | 0 (0) | 0 (0) |
| DRC | 102 (34) | 95 (93) | 16 (17) | 16 (17) | 2 (2.1) |
| Ivory Coast | 162 (62) | 31 (19) | 0 (0) | 14 (45) | 4 (13) |
| Mali | NA | 21 | 2 (9) | NA6 | 2 (9.5) |
| Niger | 59 (95) | 48 (81) | 1(2) | 4 (8) | 0 (0) |
| Rwanda | 108 (47) | 101 (94) | 9 (60) | 0 (0) | 0 (0) |
| Senegal | NA | 39 | 1 (2.3) | NA5 | NA |
| Togo | 20 (95) | 19 (95) | 1 (5.3) | NA5 | NA |
| Total | 711 | 573 (81) | 72 (13) | 36 (6.3) | 8 (1.4) |
Number (n) and percentage (%) for samples at each study step.
DRC: The Democratic Republic of the Congo. CAR: Central African Republic. Pre-XDR: resistant to either fluoroquinolone or second line injectable (SLI). XDR: resistant to both fluoroquinolone and SLI. NR: not representative. NA: not applicable.
1 The number of samples received at the Supranational Reference Laboratories as proportion of the number of patients recruited.
2Number of samples stored versus numbers diagnosed per the WHO report for the same period for the whole country.
3Number of isolates with analyzable sequences as proportion of total samples stored.
4The proportion of pre-XDR or XDR in these columns corresponds to the ratio of pre-XDR or XDR to the total isolates included in this analysis, it therefore does not reflect the general prevalence of pre-XDR or XDR TB in the respective countries.
5FQ was not known.
6FQ was not known for all isolates (partial).